InvestSMART

BlinkLab Limited (ASX: BB1) - Share Price

Current share price for BB1 : $0.605 0.015 (2.42%)+

BlinkLab Limited (BB1), an ASX-listed company,, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism and ADHD. The Company's most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old.

BB1 General Information +

ASX Code BB1
Website http://www.blinklab.org
Industry/Sector Health Care Technology
Market Cap ($M) 92
BB1 Share Price $0.605
Day High $0.630
Day Low $0.605
Last Close $0.620
BB1 Share Price Movement $0.02 ( 2.42% )
Prices as at 12:55, 9 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

BlinkLab Limited (BB1) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from BlinkLab Limited (BB1) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

BlinkLab Limited (BB1) price-sensitive announcements

BB1 - Quarterly Activities/Appendix 4C Cash Flow Report
BlinkLab Limited, a leader in digital healthcare, has made significant advancements in its
BlinkLab Limited (BB1)
30 Apr 2026 | 8:39 AM
BB1 - BlinkLab Secures A$17.5M to Launch Autism Diagnostic Aid
BlinkLab Limited, a digital healthcare company listed as ASX:BB1, announced it has secured
BlinkLab Limited (BB1)
16 Apr 2026 | 9:27 AM
BB1 - Trading Halt
BlinkLab Limited (ASX: BB1) has requested a trading halt pending an announcement related t
BlinkLab Limited (BB1)
14 Apr 2026 | 9:00 AM
BB1 - Validation Program Commences-FDA 510(k) - First Participant
BlinkLab Limited, listed on the ASX under the symbol BB1, has announced the commencement o
BlinkLab Limited (BB1)
24 Mar 2026 | 9:35 AM

BlinkLab Limited (BB1) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $92 Letter to Shareholders & Proxy Form 22 May 2026 11:22AM $0.710 $0.605 fallen by 14.79%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $92 Notice of General Meeting & Proxy Form 22 May 2026 11:20AM $0.710 $0.605 fallen by 14.79%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $92 Therapy Evaluation for Neurodevelopmental Conditions 19 May 2026 9:46AM $0.665 $0.605 fallen by 9.02%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $92 BB1 to present at Stocks in the Vines Investor Access Day 14 May 2026 9:33AM $0.660 $0.605 fallen by 8.33%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $92 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 8:39AM $0.665 $0.605 fallen by 9.02%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $92 Section 708A Notice 23 Apr 2026 9:46AM $0.710 $0.605 fallen by 14.79%

BB1 Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$5.71 -$5.60 112.60% 0.00 0.00 0.00% 0.0%
2024A -$1.75 -$2.60 283.80% 0.00 0.00 0.00% 0.0%
2023A -$0.68 -$0.70 38.80% 0.00 0.00 0.00% 0.0%

BB1 Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
4DMedical Limited (4DX) $2,333M 0.3304 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
BlinkLab Limited (BB1) $96M 1.1264 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Pro Medicus Limited (PME) $16,635M 0.3919 0.2545 0.2962 144.6231 115.2838 88.9404 0.35% 0.44% 0.58%

BB1 Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 8.60 0.00
Market 0.34 12.90 1.18 0.71
Sector 0.65 20.40 1.61 3.26

BB1 Directors

Name Position Start Date
Dr Hendrikus Johannes Boele Chief Executive Officer, Managing Director 17 Dec 2025
Dr Anton Uvarov Executive Director 2 Apr 2024
Mr Brian Willoughby Leedman Non-Executive Chairman, Non-Executive Director 15 Dec 2023
Dr Richard Miles Hopkins Non-Executive Director 18 Jan 2024

BlinkLab Limited (BB1) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
9 Jul 2025 LEEDMAN, Brian Issued Indirect Shares 166,667 $0.300 $50,000.000
9 Jul 2025 LEEDMAN, Brian Issued Options 500,000 $0.131 $65,500.000
9 Jul 2025 MORGAN, Jane Issued Direct Shares 166,666 $0.300 $50,000.000

See all changes in directors' interest & trades for BlinkLab Limited (BB1) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

BB1 Management

Name Position
Sebastiaan K.E. Koekkoek Chief Scientific Officer
Cornelis Pieter Boele Chief Technology Officer
Christopher (Chris) Bryan Achurch Company Secretary

BB1 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in BlinkLab Limited (BB1). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
9,316,667 (7.44%) Yulia Uvarova
6,783,333 (5.41%) Cason Holding BV
5,775,000 (4.61%) Bello Holding BV
5,775,000 (4.61%) Inacea Holding BV

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.